Existing knowledge is deficient in the epidemiology of endocrine/metabolic disorders related to SARS-CoV-2 (COVID-19).  Understanding the “cause and effects” of COVD-19 on endocrine/metabolic disorders can decrease morbidity and mortality worldwide.  Identifying the independent parameters based on age, sex, and illness to understand the effect of SARS-Cov2 on the different endocrine/metabolic disorders will be carried out using the fixed and random-effects meta-analysis models as appropriate. Subsequently, PubMed, Scopus, and Google Scholar databases were searched till June-2022, using suitable keywords.  Based on our analysis, COVID-19 shows a high prevalence and incidence of common endocrine and metabolic disorders (hyperglycemia, hyperlipidemia, and altered thyroid as well as pituitary functions). Interestingly, hyperglycemic and hyperlipidemic conditions can trigger the release of proxidants/pro-inflammatory markers, induce hypoxia leading to organ failure.  Furthermore, sex differences in response to inflammation were observed in COVID-19 patients. Age-associated decreases in estrogen and testosterone mediate proinflammatory mediators in older adults. On the other hand, hyperglycemic environment facilitates entry of COVID-19 by enhancing the surface expression of angiotensin converting enzyme2 (ACE2) through the hyperinsulinemia-mediated reduction in protease activity (ADAMTS17). These endocrine/metabolic pathologies can cause obesity and increased risk of cardiovascular diseases, decreasing the lifespan drastically. Delineating the etiopathology of these conditions will provide clues to risk factors and identify areas to allocate public health and research resources.